Loading...
NPI 1952343782 · Honolulu, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Honolulu, Hawaii. This profile covers 11 Medicare and 13 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 848 Ala Lilikoi St |
| City | Honolulu |
| State | HI |
| ZIP | 96818 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $334.4K |
| Medicaid | $68K |
Business profile and service mix are consistent with a community/retail pharmacy focused on immunizations and COVID services: the top Medicare revenue drivers are vaccine and vaccine-administration codes such as 91320, 90694, 90480 and administration codes like G0008, and the provider also reports high-volume COVID test provisioning via K1034. Claim counts and per-claim payments (for example, 91320: 927 claims, $128 avg paid/claim, $118.7K revenue) show on-site administration and dispensing activity rather than specialist procedural care.
Medicare revenue is materially larger than Medicaid revenue for this NPI: total Medicare revenue is $334.4K compared with total Medicaid revenue of $68K, indicating Medicare is the dominant payer in scale for this location. This suggests payer mix and reimbursement profile are weighted toward Medicare-covered vaccine and testing services.
Revenue concentration is high on both payers: the top 3 Medicare codes account for 60.9% of this provider's total Medicare revenue, and the top 3 Medicaid codes account for 60.9% of this provider's total Medicaid revenue. That concentration highlights dependence on a small set of vaccination and COVID-related codes for the majority of billed revenue.
National competitive standing on Medicare shows above-typical volume for multiple vaccine and COVID codes: 91320 ranks #84 of 27083 providers nationally (100th percentile; typical, unremarkable volume), 90694 ranks #635 of 51679 (99th percentile), 90480 ranks #169 of 46950 (100th percentile), and K1034 ranks #752 of 30143 (98th percentile). These high national percentiles indicate the pharmacy is a consistently active immunizer/test provider relative to peers rather than a low-volume outpost.
State-level competitive standing on Medicaid is similarly concentrated but more modest in scale: 0002A and 0001A together contribute $16.5K and $14.3K respectively (24.2% and 20.9% of Medicaid revenue) and rank in the roughly 78th–80th percentiles among in-state peers. 91320 also appears in the top Medicaid codes with $10.8K revenue (15.9%) and ranks #4 of 19 in-state, positioning the pharmacy among the more active in-state COVID vaccine administrators but not necessarily dominant across all vaccine services.
Statistical outliers and atypical signals are limited but present: code 0121A is described as notably above typical national volume (rank #13 of 713 providers nationally, 98th percentile), which stands out against otherwise characterizations of "typical, unremarkable volume" for many vaccine codes. Conversely, some Medicaid compounding/dispensing activity (S9430) shows 41 claims with $0 avg paid/claim and $0 revenue, indicating submitted compounding claims are not producing measurable Medicaid reimbursement.
Operational risk and business implications arise from the narrow revenue base: heavy reliance on a small set of vaccination and COVID-testing codes (top-3 share 60.9% for each payer) creates sensitivity to seasonal demand and payer policy changes for immunizations and over-the-counter test provisioning. For payer or network planning, this profile suggests the location is valuable for immunization access but may have limited service diversification beyond vaccines and test distribution.
Tenure and stability: the NPI was enumerated on 2006-06-13 (~20 years ago), indicating a long-standing registration in the Medicare/Medicaid system. That tenure, combined with the observed high percentiles on vaccine-related codes, supports interpreting the billing pattern as an established retail pharmacy immunization/test site rather than a new entrant with transient volume.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 930 | $130 | $118.7K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 4,040 | $10 | $44.5K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 540 | $80 | $40.6K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 930 | $40 | $39.9K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 110 | $280 | $29.8K |
| G0008 | Administration of influenza virus vaccine | 790 | $30 | $24.4K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 230 | $70 | $16.8K |
| 0124A | N/A | 340 | $40 | $14.6K |
| 0121A | N/A | 60 | $40 | $2.6K |
| 90732 | The provider intramuscularly or subcutaneously injects pneumococcal polysaccharide vaccine in an individual two years or older. This vaccine provides protection against meningitis and pneumonia that… | 10 | $130 | $1.7K |
Showing 1–10 of 11
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 11 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0002A | N/A | 410 | $40 | $16.5K |
| 0001A | N/A | 390 | $40 | $14.3K |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 100 | $100 | $10.8K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 580 | $10 | $6.4K |
| 0004A | N/A | 130 | $30 | $4.3K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 100 | $40 | $4K |
| 0054A | N/A | 90 | $40 | $3.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 210 | $20 | $3.6K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 100 | $20 | $2.2K |
| 0124A | N/A | 40 | $40 | $1.7K |
Showing 1–10 of 13
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
13 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 0002A | N/A | 17 | 70 | 160 | $40 | $20.8K |
| 0001A | N/A | 17 | 80 | 140 | $30 | $18.4K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 51 | 230 | 140 | $20 | $16.1K |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 4 | 20 | 30 | $120 | $12.1K |
| 0004A | N/A | 15 | 50 | 50 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 62 | 180 | 120 | $10 | $4.7K |
| 0054A | N/A | 13 | 40 | 80 | $30 | $4.5K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 11 | 60 | 50 | $30 | $2.8K |
| 0124A | N/A | 17 | 40 | 40 | $20 | $1.7K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 15 | 60 | 50 | $20 | $1.3K |
Showing 1–10 of 13
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Liberty Dialysis - Hawaii LLC | HI | End-Stage Renal Disease (ESRD) Treatment Clinic/Center | $0 | $6.7M |
| Health Services Hawaii 808, Inc. | HI | Case Management Agency | $0 | $173.1K |
| Longs Drug Stores California LLC | HI | Pharmacy | $94.8K | $8.9K |
| Kyle Shoji | HI | Occupational Therapist | $920 | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.